Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

Leukemia. 2015 Feb;29(2):510-4. doi: 10.1038/leu.2014.300. Epub 2014 Oct 13.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Apoptosis
  • Benzamides / administration & dosage*
  • Boronic Acids / administration & dosage*
  • Bortezomib
  • Cell Line
  • Cell Line, Tumor
  • Cell Proliferation
  • Cell Survival
  • Drug Screening Assays, Antitumor
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors*
  • Humans
  • Mice
  • Mice, SCID
  • Monomeric GTP-Binding Proteins / metabolism
  • Multiple Myeloma / drug therapy*
  • Mutation
  • Neoplasm Transplantation
  • Pyrazines / administration & dosage*
  • Pyrazoles / administration & dosage*
  • Retinal Pigment Epithelium / cytology

Substances

  • Antineoplastic Agents
  • Benzamides
  • Boronic Acids
  • HSP90 Heat-Shock Proteins
  • HSP90AA2P protein, human
  • HSP90AB1 protein, human
  • Pyrazines
  • Pyrazoles
  • TAS-116
  • Bortezomib
  • Monomeric GTP-Binding Proteins
  • Nras protein, mouse